Proqr Therapeutics Bv Stock Probability of Future Stock Price Finishing Over 19.55
| PRQR Stock | USD 1.65 0.02 1.23% |
ProQR |
ProQR Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ProQR Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ProQR Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ProQR Therapeutics generated a negative expected return over the last 90 days | |
| ProQR Therapeutics may become a speculative penny stock | |
| ProQR Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 18.91 M. Net Loss for the year was (27.76 M) with profit before overhead, payroll, taxes, and interest of 19.55 M. | |
| ProQR Therapeutics BV currently holds about 156.4 M in cash with (36.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 18.0% of the company outstanding shares are owned by corporate insiders |
ProQR Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ProQR Stock often depends not only on the future outlook of the current and potential ProQR Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ProQR Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 81.7 M | |
| Cash And Short Term Investments | 149.4 M |
ProQR Therapeutics Technical Analysis
ProQR Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. ProQR Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of ProQR Therapeutics BV. In general, you should focus on analyzing ProQR Stock price patterns and their correlations with different microeconomic environments and drivers.
ProQR Therapeutics Predictive Forecast Models
ProQR Therapeutics' time-series forecasting models is one of many ProQR Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary ProQR Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about ProQR Therapeutics
Checking the ongoing alerts about ProQR Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for ProQR Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| ProQR Therapeutics generated a negative expected return over the last 90 days | |
| ProQR Therapeutics may become a speculative penny stock | |
| ProQR Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 18.91 M. Net Loss for the year was (27.76 M) with profit before overhead, payroll, taxes, and interest of 19.55 M. | |
| ProQR Therapeutics BV currently holds about 156.4 M in cash with (36.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 18.0% of the company outstanding shares are owned by corporate insiders |
Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.